Patents by Inventor Stanley T. Crooke

Stanley T. Crooke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200157548
    Abstract: Provided herein are compositions and methods for non-parenteral delivery of conjugated oligomeric compounds. In certain embodiments, compositions and methods are provided for oral delivery of conjugated oligomeric compounds. In certain embodiments, the oligomeric compounds are conjugated to one or more N-acetylgalactosamines or N-acetylgalactosamine analogues.
    Type: Application
    Filed: June 21, 2019
    Publication date: May 21, 2020
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Stanley T. Crooke
  • Patent number: 10619157
    Abstract: In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of STAT3 mRNA or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate B-cell lymphoma or hepatocellular carcinoma.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: April 14, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Mason Yamashita
  • Patent number: 10478449
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: November 19, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Patent number: 10370659
    Abstract: In certain embodiments, the present disclosure provides compounds and methods for increasing the antisense activity of an antisense compound in a cell. In certain embodiments, the present disclosure provides methods for identifying antisense compounds having high activity. In certain embodiments, the present disclosure provides methods for identifying antisense compounds that bind to enhancer or repressor proteins.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: August 6, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Xue-hai Liang, Wen Shen, Stanley T. Crooke
  • Publication number: 20190127737
    Abstract: The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression.
    Type: Application
    Filed: November 5, 2018
    Publication date: May 2, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Walter F. Lima, Garth A. Kinberger, Heather Murray, Eric E. Swayze, Stanley T. Crooke
  • Publication number: 20180346907
    Abstract: In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of STAT3 mRNA or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate B-cell lymphoma or hepatocellular carcinoma.
    Type: Application
    Filed: November 27, 2017
    Publication date: December 6, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Stanley T. CROOKE, Mason YAMASHITA
  • Publication number: 20180245084
    Abstract: Provided herein are compositions and methods for non-parenteral delivery of conjugated oligomeric compounds. In certain embodiments, compositions and methods are provided for oral delivery of conjugated oligomeric compounds. In certain embodiments, the oligomeric compounds are conjugated to one or more N-acetylgalactosamines or N-acetylgalactosamine analogues.
    Type: Application
    Filed: January 22, 2018
    Publication date: August 30, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Stanley T. Crooke
  • Publication number: 20180201930
    Abstract: The present invention provides compounds and methods for modulating target nucleic acids found in organelles or sub-organelles of cells. The invention includes, but is not limited to compounds and methods that modulate target nucleic acids in a sub-nuclear organelle, such as the nucleolus and/or a cajal body. In certain embodiments, the cell is in an animal.
    Type: Application
    Filed: November 10, 2017
    Publication date: July 19, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Xue-hai Liang, Stanley T. Crooke
  • Publication number: 20180200282
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Application
    Filed: March 7, 2018
    Publication date: July 19, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Publication number: 20180148718
    Abstract: In certain embodiments, the present disclosure provides compounds and methods for increasing the antisense activity of an antisense compound in a cell. In certain embodiments, the present disclosure provides methods for identifying antisense compounds having high activity. In certain embodiments, the present disclosure provides methods for identifying antisense compounds that bind to enhancer or repressor proteins.
    Type: Application
    Filed: February 23, 2016
    Publication date: May 31, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Xue-hai Liang, Wen Shen, Stanley T. Crooke
  • Publication number: 20180104271
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Application
    Filed: December 21, 2017
    Publication date: April 19, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Publication number: 20180104272
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Application
    Filed: December 21, 2017
    Publication date: April 19, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Patent number: 9943539
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 17, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Patent number: 9943538
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 17, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Publication number: 20180087107
    Abstract: The present invention provides compounds and methods for competitive modulation of microRNAs. Such copounds and methods have profound effects on cells.
    Type: Application
    Filed: June 27, 2017
    Publication date: March 29, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Xue-hai Liang, Stanley T. Crooke
  • Publication number: 20180028555
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Patent number: 9873876
    Abstract: In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of ST AT3 mRNA or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate B-cell lymphoma or hepatocellular carcinoma. The STAT (signal transducers and activators of transcription) family of proteins are DNA-binding proteins that play a dual role in signal transduction and activation of transcription.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: January 23, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Mason Yamashita
  • Publication number: 20180009837
    Abstract: In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell. In certain embodiments, the compounds comprise a translation suppression element inhibitor. In certain embodiments, the translation suppression element inhibitor is a uORF inhibitor. In certain embodiments, the uORF inhibitor is an antisense compound.
    Type: Application
    Filed: November 16, 2015
    Publication date: January 11, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Xue-hai Liang, Wen Shen
  • Patent number: 9856473
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: January 2, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Stanley T. Crooke, Timothy Vickers
  • Patent number: 9845468
    Abstract: The present invention provides compounds and methods for modulating target nucleic acids found in organelles or sub-organelles of cells. The invention includes, but is not limited to compounds and methods that modulate target nucleic acids in a sub-nuclear organelle, such as the nucleolus and/or a cajal body. In certain embodiments, the cell is in an animal.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: December 19, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Xue-hai Liang, Stanley T. Crooke